secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2022-01-31T23:59:59+00:00
Accession:  0001193125-22-023545
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex raises $9.7M in private placement of 8.75M shares at $1.11; January equity total $13.2M
--------------------------------------------------------------------------------

- Private placement closed Jan 31 with 8,747,744 shares at $1.11/share; gross proceeds ~$9.7M after amendment adding 2.8M shares.
- Affiliated investors include CEO Maurice Zauderer ($2M), Chairman Albert Friedberg ($2M), and director Jacob Frieberg.
- Additional $3.5M raised via ATM sales earlier in January at weighted avg $1.16/share, bringing month total to ~$13.2M.
- Proceeds will fund development of lead drug candidate pepinemab in cancer and neurodegenerative disease.
- Registration rights agreement requires filing resale shelf within 75 days; failure triggers liquidated damages.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522023545/0001193125-22-023545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522023545/d285729d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-023545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer